Difference between revisions of "Allopurinol (Zyloprim)"
Jump to navigation
Jump to search
m |
|||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
* 8/19/1966: Initial FDA approval | * 8/19/1966: Initial FDA approval | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:Xanthine oxidase inhibitors]] | ||
[[Category:Drugs FDA approved in 1966]] | [[Category:Drugs FDA approved in 1966]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 13:14, 16 September 2017
General information
Class/mechanism: Xanthine oxidase inhibitor.
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.
History of changes in FDA indication
- 8/19/1966: Initial FDA approval
Also known as
- Brand names: Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway